Skip to content
    British Patient Capital logo

    British Patient Capital

    Sheffield, United KingdomFounded 2018
    www.british-business-bank.co.ukLinkedIn
    Biotech & Life SciencesFintechSaaS

    British Patient Capital was a commercial subsidiary of the British Business Bank, mandated to enable long-term investment in innovative UK companies led by ambitious entrepreneurs. It was the UK's largest domestic investor in venture and growth capital, with over £2.3 billion in total fund and co-investment commitments.

    Deal activity decreased year-over-year (1 deal in the last 12 months vs 12 prior). Average disclosed round size is $91.6M (across 38 rounds with reported amounts).

    Find people at British Patient Capital on Goldilocks AI

    Portfolio

    37

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    1

    Team

    IC

    Ian Connatty

    Managing Partner / Deputy Chief Investment Officer

    CH

    Christine Hockley

    Managing Director, Funds

    AW

    Alexandra Woodman

    Investment Analyst

    AA

    Anu Adebajo

    Senior Investment Manager

    DW

    David Woods

    Senior Investment Manager, Funds

    PG

    Pinky Ghosh

    Investment Manager

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    63 investments
    CompanyRoundAmountDate
    Quantum Motion logoQuantum MotionSeries B—May 2026
    Paragraf logoParagrafSeries C$55MAug 2025
    MMaxion Therapeutics Ltd.Series A$72MMar 2025
    Quantexa logoQuantexaSeries F—Mar 2025
    Cambridge GaN Devices logoCambridge GaN DevicesSeries C—Feb 2025
    Maxion logoMaxionSeries A$72MJan 2025
    MMaxion Therapeutics Ltd.Series A$72MJan 2025
    Quantexa logoQuantexaSeries B$22.7MJan 2025
    Tokamak Energy logoTokamak EnergySeries D—Nov 2024
    Tokamak Energy logoTokamak EnergySeries C—Nov 2024
    NNuclera LtdSeries C$75MOct 2024
    NNuclera LtdSeries A$75MOct 2024
    Purespring logoPurespringSeries B$105MOct 2024
    PPurespring TherapeuticsSeries B$105MOct 2024
    Form3 logoForm3Series C$160MSep 2024
    Epsilogen Ltd logoEpsilogen LtdSeries B—Sep 2024
    Grey Wolf Therapeutics logoGrey Wolf TherapeuticsSeries B$50MMay 2024
    Stream Holdings logoStream HoldingsSeries B—Apr 2024
    Phagenesis logoPhagenesisSeries D—Mar 2024
    Curve Therapeutics logoCurve TherapeuticsSeries A$40.5MFeb 2024
    MMaxion Therapeutics Ltd.Series A$16MFeb 2024
    Epsilogen Ltd logoEpsilogen LtdSeries B—Jan 2024
    PPurespring TherapeuticsSeries B—Jan 2024
    Tokamak logoTokamakUnknown$125MJan 2024
    Purespring logoPurespringSeries B—Jan 2024
    Page 1 of 3

    Top Co-Investors

    British Business Bank16 shared
    Oxford Science Enterprises11 shared
    AlbionVC9 shared
    Cambridge Innovation Capital8 shared
    Parkwalk Advisors7 shared
    Sofinnova Partners7 shared
    IQ Capital6 shared
    Northern Gritstone6 shared
    Evolution Equity Partners5 shared
    Dawn Capital5 shared
    Warburg Pincus LLC5 shared
    Octopus Ventures5 shared
    INKEF Capital5 shared
    GG15 shared
    BGF5 shared
    Pfizer Ventures5 shared
    In-Q-Tel5 shared
    Prosperity7 Ventures5 shared
    HSBC4 shared
    ABN AMRO Ventures4 shared

    Last updated: 7 October 2026